Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
G. D'Amico, L. Pagliaro, J. Bosch.
The treatment of portal hypertension: a meta-analytic review.
Hepatology, 22 (1995), pp. 332-354
[2.]
R. De Franchis.
Updating consensus in portal hypertension: report of the Baveno III consensus workshop on definitions, methodology and therapeutic strategies in portal hypertension.
J Hepatol, 33 (2000), pp. 846-852
[3.]
J. Bosch, J.C. García-Pagán, F. Feu, A. Luca, M. Fernández, P. Pizcueta, et al.
New approaches in the pharmacologic treatment of portal hypertension.
J Hepatol, 17 (1993), pp. 41-45
[4.]
J. Polio, R. Groszmann.
J. Hemodinamic factors involved in the development and rupture of esophageal varices: a pathophysiologic approach to treatment.
Semin Liver Dis, 6 (1986), pp. 318-331
[5.]
G. García-Tsao, R.J. Groszmann, R.L. Fisher, H.O. Conn, C.E. Atterbury, M. Glickman.
Portal pressure, presence of gastroesophageal varices and variceal bleeding.
Hepatology, 5 (1985), pp. 419-424
[6.]
P.S. Bhatal, H.J. Grossmann.
Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators.
J Hepatol, 1 (1985), pp. 325-337
[7.]
R. Wiest, R.J. Gorszmann.
The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough.
Hepatology, 35 (2002), pp. 478-491
[8.]
J. Bosch.
García-Pagán JC. Complications of cirrhosis. I. Portal hypertension.
J Hepatol, 32 (2000), pp. 141-156
[9.]
J.C. García-Pagán, J.M. Salmerón, F. Feu, A. Luca, P. Ginés, P. Pizcueta, et al.
Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis.
Hepatology, 19 (1994), pp. 1095-1099
[10.]
J.C. García-Pagán, F. Feu, A. Castells, A. Luca, R.C. Hermida, F. Rivera, et al.
Circadian variations of portal pressure and variceal hemorrhage in patients with cirrhosis.
Hepatology, 19 (1994), pp. 595-601
[11.]
D. Álvarez, D. Golombek, P. López, M. De Las Heras, L. Viola, S. Sánchez, et al.
Diurnal fluctuations of portal and systemic hemodynamic parameters in patients with cirrhosis.
Hepatology, 20 (1994), pp. 1198-1203
[12.]
P.A. McCormick, R. Dick, M. Graffeo, D. Wagstaff, A. Medden, N. McIntyre, et al.
The effect of non-protein liquid meals on the hepatic venous pressure gradient in patients with cirrhosis.
J Hepatol, 11 (1990), pp. 221-225
[13.]
S. O'Brien, M. Keogan, S. Patchett, P.A. McCormick, N. Afdhal, J.E. Hegarty.
Postprandial changes in portal haemodynamics in patients with cirrhosis.
Gut, 33 (1992), pp. 364-367
[14.]
G. Silva, F. Fluxá, G. Bresky, C. Backhouse, M. Palma, M. Ruiz, et al.
Splanchnic and systemic hemodynamics in early abstinence and after ethanol administration in non-cirrhotic alcoholic patients.
J Hepatol, 20 (1994), pp. 494-499
[15.]
A. Luca, F. Feu, J.C. García-Pagán, J.C. López-Talavera, J. Caballería, J. Bosch, et al.
Ethanol consumption worsens hepatic hemodynamics in patients with alcoholic cirrhosis and portal hypertension.
Hepatology, 18 (1993), pp. 108A
[16.]
J.C. García-Pagán, C. Santos, J.A. Barberá, F. Feu, A. Luca, J. Roca, R. Rodríguez-Roisin, et al.
Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension.
Gastroenterology, 111 (1996), pp. 1300-1306
[17.]
P.A. McCormick, S.A. Jenkins, N. McIntyre, A.K. Burroughs.
Why portal hypertensive varices bleed and bleed: a hypotesis.
Gut, 36 (1995), pp. 100-103
[18.]
J. Reichen.
Liver function and pharmacological considerations in pathogenesis and treatment of portal hypertension.
Hepatology, 11 (1990), pp. 1066-1078
[19.]
A.W. Schneider, J.F. Kalk, C.P. Klein.
Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis.
Hepatology, 29 (1999), pp. 334-339
[20.]
M. Schepke, E. Werner, E. Bieker, P. Schiedermaier, U. Hofer, G. Layer, et al.
The angiotensin II receptor antagonist irbesartan for the treatment of portal hypertension: A placebo-controlled, double-blind study.
Hepatology, 32 (2000), pp. 406A
[21.]
J. González-Abraldes, A. Albillos, R. Bañares, L. Ruiz Del Árbol, E. Moitinho, C. Rodríguez, et al.
Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis.
Gastroenterology, 121 (2001), pp. 382-388
[22.]
J.H. Henriksen, H. Ring-Larsen.
Renal effects of drugs in the treatment of portal hypertension.
Hepatology, 18 (1993), pp. 688-695
[23.]
G. García-Tsao.
Current management of the complications of cirrhosis and portal hypertension: Variceal hemorrhage, ascites, and spontaneous bacterial peritonitis.
Gastroenterology, 120 (2001), pp. 726-748
[24.]
M. Angelico, L. Carli, C. Piat, S. Gentile, V. Rinaldi, E. Bologna, et al.
Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis.
Gastroenterology, 104 (1993), pp. 1460-1465
[25.]
J.C. García-Pagán, C. Villanueva, M.C. Vila, A. Albillos, J. Genescà, L. Ruiz del Árbol, et al.
and Members of the MOVE group. Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta blockers.
Gastroenterology, 121 (2001), pp. 908-914
[26.]
T.D. Boyer.
Pharmacologic treatment of portal hypertension: past, present and future.
Hepatology, 34 (2001), pp. 834-839
[27.]
E. Stroess, H. Koomans, T. Rabelink.
Vascular function in the forearm of hypercholesterolemic patients off and on lipid-lowering medication.
Lancet, 346 (1980), pp. 467-471
[28.]
M. Creager, S. Gallagher, X. Girerd, S. Coleman, V. Dzau, J. Cooke.
L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans.
J Clin Invest, 90 (1992), pp. 1248-1253
[29.]
T. Gupta, R. Groszmann.
Administration of L-arginine, the physiological precursor of nitric oxide, reduces portal perfusion pressure and ameliorates hepatic vascular hyperreactivity in experimental cirrhosis.
Hepatology, 20 (1994), pp. 200A
[30.]
F. Cosentino, S. Patton, L. D'Uscio, E. Werner, G. Werner-Felmayer, P. Moreau, et al.
Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats.
J Clin Invest, 101 (1998), pp. 1530-1537
[31.]
J. Saavedra, T. Billiar, D. Williams, Y. Kim, S. Watkins, L. Keefer.
Targeting nitric oxide delivery in vivo. Design of a liver-selective NO donor prodrug that blocks tumor necrosis-alpha-induced apoptosis and toxicity in the liver.
J Med Chem, 40 (1997), pp. 1947-1954
[32.]
F. Moal, E. Vuillemin, J. Wang, N. Veal, F. Oberti, P. Cales.
Chronic Hemodynamic Effects Of A New Liver Specific No Donor (V-PYRRO/NO) In Bile Duct Ligated (BDL) Rats.
Gastroenterology, 118 (2000), pp. 978A
[33.]
Q. Yu, R. Shao, H. Qian, S. George, D. Rockey.
Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension.
J Clin Invest, 105 (2000), pp. 741-748
[34.]
A. Omasta, F. Nevens, P. Vermaelen, J. Fevery.
CENOS Gene Transfer Enhances NO Production And NOS Protein Expression In The CCl4 Cirrhotic Rat Liver Resulting In Prolonged Decrease Of Portal Pressure.
Gastroenterology, 118 (2000), pp. 905A
[35.]
D.C. Rockey, R.A. Weisinger.
Endothelin-induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance.
Hepatology, 24 (1996), pp. 233-240
[36.]
F. Feu, J.M. Bordas, J.C. García-Pagán, J. Bosch, J. Rodés.
Doubleblind investigation of the effects of propranolol and placebo on the pressure of esophageal varices in patients with portal hypertension.
Hepatology, 13 (1991), pp. 917-922
[37.]
G. D'Amico, L. Pagliaro, J. Bosch.
Pharmacological treatment of portal hypertension: an evidence-based approach.
Semin Liver Dis, 19 (1999), pp. 475-505
[38.]
T. Poynard, P. Calès, L. Pasta, G. Ideo, J.P. Pascal, L. Pagliaro, et al.
and the Franco-Italian Multicenter Study Group. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices: an analysis of data and prognostic factors in 589 patients from four randomized clinical trials.
N Engl J Med, 324 (1991), pp. 1532-1538
[39.]
N.D. Grace, R.J. Groszmann, G. Garcia-Tsao, A.K. Burroughs, L. Pagliaro, R.W. Makuch, et al.
Portal hypertension and variceal bleeding: An AASLD single topic symposium.
Hepatology, 28 (1998), pp. 868-880
[40.]
A.K. Burroughs, D. Patch.
Drug therapy: comparison with other therapies for portal hypertension.
Treatments in hepatology, pp. 41-49
[41.]
J. Bosch, D. Kravetz, J. Rodes.
Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver. Comparison with vasopresin.
Gastroenterology, 80 (1981), pp. 518-525
[42.]
C.C. Sieber, P.G. Mosca, R.J. Groszmann.
Effect of somatostatin on mesenteric vascular resistance in normal and portal hypertensive rats.
Am J Physiol, 262 (1992), pp. 274G-277G
[43.]
D. Kravetz, J. Bosch, M.T. Arderiu, M.P. Pizcueta, R. Casamitjana, F. Rivera, et al.
Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats.
Am J Physiol, 254 (1988), pp. 322G-328G
[44.]
R. Chatila, L. Ferayorni, T.K. Grupta, R.J. Groszmann.
Local arterial vasoconstriction induced by octreotide in patients with cirrhosis.
Hepatology, 32 (2000), pp. 419-425
[45.]
R. Wiest, M.H. Tsai, R.J. Groszmann.
Octreotide potentiates PKCdependent vasoconstrictors in portal-hypertensive and control rats.
Gastroenterology, 120 (2001), pp. 975-983
[46.]
G.E. Sonnenberg, U. Keller, A. Perruchud, D. Burckhardt, K. Gyr.
Effect of somatostatin on splanchnic haemodynamics in patients with cirrhosis of the liver and in normal subjects.
Gastroenterology, 80 (1981), pp. 526-532
[47.]
C. Merkel, A. Gatta, R. Zuin, G.F. Finucci, L. Arnaboldi, A. Roul.
Effects of somatostatin on splanchnic haemodynamics in patients with liver cirrhosis and portal hypertension.
Digestion, 32 (1985), pp. 92-98
[48.]
I. Cirera, F. Feu, A. Luca, J.C. García-Pagán, M. Fernández, A. Escorsell, et al.
Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis. A double-blind hemodynamic investigation.
Hepatology, 22 (1995), pp. 106-111
[49.]
E. Moitinho, R. Planas, R. Bañares, A. Albillos, L. Ruiz del Árbol, C. Gálvez, et al.
Variceal Bleeding Study Group. Multicenter randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding.
J Hepatol, 35 (2001), pp. 712-718
[50.]
C. Villanueva, J. Ortiz, J. Miñana, G. Soriano, M. Sàbat, J. Boadas, et al.
Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding.
Gastroenterology, 121 (2001), pp. 110-117
[51.]
L. Chen, R.J. Groszmann.
Blood in the gastric lumen increases splanchnic bloof flow and portal pressure in portal-hypertensive rats.
Gastroenterology, 111 (1996), pp. 1103-1110
[52.]
D. Kravetz, E. Sikuler, R.J. Groszmann.
Splanchnic and systemic hemodynamics in portal hypertensive rats during hemorrhage and blood volume restitution.
Gastroenterology, 90 (1986), pp. 1232-1240
[53.]
J.D. Vorobioff, M. Gamen, D. Kravetz, E. Picabea, R. Villavicencio, J. Bordato, et al.
Effects of long-term propranolol and octreotide on postprandial hemodynamics in cirrhosis: a randomized, controlled trial.
Gastroenterology, 122 (2002), pp. 916-922
[54.]
C. Sabbá, G. Ferraioli, P. Buonamico, T. Mahl, K.J.W. Taylor, E. Lerner, et al.
A randomized study of propranolol on postprandial hyperemia in cirrhotic patients.
Gastroenterology, 102 (1992), pp. 1009-1016
[55.]
D.A. Corley, J.P. Cello, W. Adkinsson, W.F. Ko, K. Kerlikowske.
Octreótide for acute esophageal variceal bleeding: a metaanalysis.
Gastroernterology, 120 (2001), pp. 946-954
[56.]
P. Calés, C. Masliah, B. Bernard, P.P. Garnier, C. Silvain, N. Szostak-Talbodec, et al.
for the french club for the study of portal hypertension. Early administration of vapreotide for variceal bleeding in patients with cirrhosis.
N Engl J Med, 334 (2001), pp. 23-28
[57.]
A. Stanley, P.C. Hayes.
Portal hypertension and variceal haemorrhage.
Lancet, 350 (1997), pp. 1235-1239
[58.]
F. Feu, L. Ruiz del Árbol, R. Bañares, R. Planas, J. Bosch.
and members of the Variceal Bleeding Study Group. Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage.
Gastroenterology, 111 (1996), pp. 1291-1299
[59.]
R.J. Kroeger, R.J. Groszmann.
The effect of the combination of nitroglycerin and propranolol on splanchnic and systemic hemodynamics in a portal hypertensive rat model.
Hepatology, 5 (1985), pp. 425-430
[60.]
R. Morillas, R. Planas, E. Cabré, A. Galán, J.C. Quer, F. Feu, et al.
Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects.
Hepatology, 20 (1994), pp. 1502-1508
[61.]
J.C. García-Pagán, M. Navasa, J. Bosch, C. Bru, P. Pizcueta, J. Rodés.
Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis.
Hepatology, 11 (1990), pp. 230-238
[62.]
J.C. Garcia-Pagán, F. Feu, J. Bosch, J. Rodés.
Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study.
Ann Intern Med, 114 (1991), pp. 869-873
[63.]
J. Gournay, C. Masliah, T. Martin, D. Perrin, J.P. Galmiche.
Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding.
Hepatology, 31 (2000), pp. 1239-1245
[64.]
C. Villanueva, J. Balanzó, M. Novella, G. Soriano, S. Sainz, X. Torras, et al.
Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding.
N Engl J Med, 334 (1996), pp. 1624-1629
[65.]
P.A. McCormick, F. Feu, C. Sabrin, R. Planas.
and the Anglo-Spanish variceal rebleeding group. Propranolol and isosorbide mononitrate versus sclerotherapy or shunt surgery for the prevention of variceal rebleeding: a randomized trial [abstract].
Hepatology, 20 (1994), pp. 106A
[66.]
C. Villanueva, J. Miñana, J. Ortiz, A. Gallego, G. Soriano, X. Torras, et al.
Endoscopic ligation compared with combined treatment with nadolol plus isosorbide mononitrate to prevent recurrent variceal bleeding.
N Engl J Med, 345 (2001), pp. 647-655
[67.]
D. Patch, C.A. Sabin, J. Goulis, G. Gerunda, L. Greenslade, C. Merkel, et al.
A randomized controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis.
Gatroenterology, 123 (2002), pp. 1013-1019
[68.]
G.H. Lo, W.C. Chen, M.H. Chen, P.I. Hsu, C.K. Lin, W.L. Tsai, et al.
Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal bleeding.
Gastroenterology, 123 (2002), pp. 728-734
[69.]
A. Escorsell, R. Bañares, J.C. García-Pagán, R. Gilabert, E. Moitinho, B. Piqueras, et al.
TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: A randomized controlled trial.
Hepatology, 35 (2002), pp. 385-392
[70.]
A. Albillos, J.C. García-Pagán, J. Iborra, J.C. Bandi, G. Cacho, M. Pérez-Paramo, et al.
Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension.
Gastroenterology, 115 (1998), pp. 116-123
[71.]
R. Bañares, E. Moitinho, A. Matilla, J.C. García-Pagán, J.L. Lampreave, C. Piera, et al.
Randomized comparison of longterm carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis.
Hepatoloy, 36 (2002), pp. 1367-1373
[72.]
R. Abecasis, D. Kravetz, E. Fasio, B. Ameigeiras, D. García, R. Iola, et al.
Nadolol plus spironolactone vs nadolol alone in the prophylaxis of the first variceal bleeding in non-ascitic cirrhotic patients. Preliminary results of a multicenter, double blind and randomized trial.
Hepatology, 26 (1997), pp. 135A
[73.]
D.M. Novick, C. Villanueva, J. Miñana, J. Balanzo.
Prevention of recurrent variceal bleeding.
N Engl J Med, 346 (2002), pp. 209-210
[74.]
R.J. Groszmann, G. Garcia-Tsao.
Endoscopic variceal banding vs pharmacological therapy for the prevention of recurrent variceal hemorrhage: What makes the difference?.
Gastroenterology, 123 (2002), pp. 1388-1391
[75.]
R.J. Groszmann, J. Bosch, N.D. Grace, H.O. Conn, G. García-Tsao, M. Navasa, et al.
Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage.
Gastroenterology, 99 (1990), pp. 1401-1407
[76.]
F. Feu, J.C. García-Pagán, J. Bosch, A. Lala, J. Tesés, A. Escorseu, et al.
Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis.
Lancet, 346 (1995), pp. 1056-1059
[77.]
J.M. López-Balaguer, M. Planella, B. González, J. Miñana, C. Aracil, E. Fort, et al.
Effects of hemodynamic response to medical treatment for variceal bleeding on other complications of cirrhosis.
Hepatology, 34 (2001), pp. 189A
[78.]
C. Bureau, J.M. Péron, L. Alric, J. Morales, J. Sánchez, K. Barange, et al.
«A la carte» treatment of portal hypertension: Adapting therapy to hemodynamic response for the prevention of bleeding.
Hepatology, 36 (2002), pp. 1361-1366
[80.]
C. Infante-Rivard, S. Esnaola, J.P. Villeneuve.
Role of endoscopic variceal sclerotherapy in the long-term management of variceal bleeding: a meta-analysis.
Gastroenterology, 96 (1989), pp. 1087-1092
[80.]
B. Bernard, D. Lebrec, P. Mathurin, P. Opolon, T. Pynard.
Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis.
J Hepatol, 26 (1997), pp. 312-324
[81.]
R.M.M. Pérez-Ayuso, J.M. Piqué, J. Bosch, J. Panés, A. González, R. Pérez, et al.
Propranolol in the prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis.
Lancet, 337 (1991), pp. 1431-1434
[82.]
J. De la Peña, M. Rivero, E. Sánchez, E. Fábrega, J. Crespo, F. Pons-Romero.
Variceal ligation compared with endoscopic sclerotherapy for variceal hemorrhage: prospective randomized trial.
Gastrointest Endosc, 49 (1999), pp. 417-423
[83.]
G.V. Stiegmann, J.S. Goff, P.A. Michaletz-Onody, J. Korula, D. Lieberman, Z.A. Saeed, et al.
Endoscopic sclerotherapy as compared with endoscopic logation for bleeding esophageal varices.
N Engl J Med, 326 (1992), pp. 1527-1532
[84.]
T.F. Imperiale, N. Chalasani.
A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding.
Hepatology, 33 (2001), pp. 802-807
[85.]
L. Laine, D. Cook.
Endoscopic ligation compared with sclerothepary for treatment of esophageal variceal bleeding. A metaanalysis.
Ann Intern Med, 123 (1995), pp. 280-287
[86.]
G.H. Lo, K.H. Lai, J.S. Cheng, M.H. Chen, M.C. Harar, P.I. Hsu, et al.
Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial.
Hepatology, 32 (2000), pp. 461-565
[87.]
L. Laine, C. Stein, V. Sharma.
Randomized comparison of ligation versus lipation plus sclerotherapy in patients with bleeding esophageal varices.
Hepatology, 110 (1996), pp. 529-533
[88.]
Z. Saeed, G. Stiegmann, F. Ramírez, R. Reveille, J. Goff, K. Hepps, et al.
Endoscopic variceal ligation is superior to combined ligation and sclerotherapy for esophageal varices: a multicenter prospective randomized trial.
Hepatology, 25 (1997), pp. 71-74
[89.]
Y.S. Cheng, S. Pan, G.S. Lien, F.M. Suk, M.S. Wu, J.N. Chen, et al.
Adjuvant sclerotherapy after ligation for the treatment of esophageal varices: A prospective, randomized long-term study.
Gastrointest Endosc, 53 (2001), pp. 566-571
[90.]
J. Argonz, D. Kravetz, A. Suárez, G. Romero, M. Bidozola, M. Passamonti, et al.
Variceal band ligation and variceal band ligation plus sclerotherapy in the prevention of recurrent variceal bleding in cirrhotic patients: a randomized, prospective and controlled trial.
Gastrointest Endosc, 51 (2000), pp. 157-163
[91.]
C. Villanueva, J. Ortiz, M. Sàbat, A. Gallego, X. Torras, G. Soriano, et al.
Somatostatin alone or combined with emergency sclerotherapy in the treatment of acute esophageal variceal bleeding: a prospective randomized trial.
Hepatology, 30 (1999), pp. 384-389
[92.]
A. Avgerinos, F. Nevens, S. Raptis.
Fevery J and the ABOVE Study Group. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial.
Lancet, 350 (1997), pp. 1495-1499
[93.]
R. Bañares, A. Albillos, D. Rincón, S. Alonso, M. González, L. Ruiz del Árbol, et al.
Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a metaanalysis.
Hepatology, 35 (2002), pp. 609-615
[94.]
S. Levacher, P. Letoumelin, D. Pateron, M. Blaise, C. Lapandry, J.L. Pourriat.
Early administration of terlipressin plus glyceryl trinatre to control active upper gastrointestinal bleeding in cirrhotic patients.
Lancet, 346 (1995), pp. 865-868
[95.]
I. Besson, P. Ingrand, B. Person, D. Boutroux, D. Heresbach, P. Bernard, et al.
Sclerotherapy with or without octreotide for acute variceal bleeding.
N Engl J Med, 333 (1995), pp. 555-560
[96.]
J.K. Sung, S.C. Chung, M.Y. Yung, C.W. Lai, Y.W. Lau, Y.T. Lee, et al.
Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation.
Lancet, 346 (1995), pp. 1666-1669
[97.]
R. De Franchis, M. Primignani.
Endoscopic treatment for portal hypertension.
Semin Liver Dis, 19 (1999), pp. 439-455
[98.]
G. D'Amico, F. Politi, A. Morabito, A. D'Antoni, D. Guerrera, G. Giannuoli, et al.
Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double-blind, randomized pragmatic trial.
Hepatology, 28 (1998), pp. 1206-1214
[99.]
R.J. Groszmann.
The hepatic venous pressure gradient: has the time arrived for its application in clinical practice?.
Hepatology, 24 (1996), pp. 739-741
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados
